ZVRA
Zevra TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The checked company sources support a better post-earnings setup: Q1 revenue materially outgrew last year, MIPLYFFA revenue and enrollments continued to build, the SDX sale added liquidity, and debt repayment left Zevra with a stronger balance sheet and more strategic flexibility [#8-K-2026-05-06] [#10-Q-2026-05-06]. AP/Zacks coverage also framed the quarter as a revenue and adjusted EPS beat versus consensus.
Posture
Constructive
Lead driver
Momentum
What changed
5 setup hits (3d) with net bullish as of 2026-06-01.
What can break
Celiprolol's DiSCOVER study remains event-driven and still had only 62 enrolled patients and two confirmed events as of March 31, 2026, leaving regulatory timing and readout cadence uncertain [#10-Q-2026-05-06].
Momentum
75
Value
41
Sentiment
70
Setup hits (3d)
5 · Net Bullish
AI TargetsBase $13.00 · Bull $18.00 · Bear $7.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $22.54
Why
Momentum75 · Δ7d +5.5
Value41 · Δ7d +0.1
Sentiment70 · Δ7d -13.7
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
75
34% active weight
Current posture
7d trendImproving
Δ7d
+5.5
Δ21d
-1.5
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
70
33% active weight
Current posture
7d trendSoftening
Δ7d
-13.7
Δ21d
+1.4
Why this grade
Composite grade A. Momentum 75.5 / Value 41.1 / Sentiment 69.8
Fundamentals (TTM)As of 2026-05-29
Fundamentals (TTM)
As of 2026-05-29
Market Cap
$685.14M
Beta
0.99
Shares Out
56.3M
P/E (TTM)
14.1
P/S (TTM)
5.56
P/FCF (TTM) · Derived
-22.13
Rev YoY
+605.4%
EPS YoY
+98.6%
Gross Margin
+93.9%
Op Margin
-103.9%
Net Debt
-$9.99M
Current Ratio
8.62
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology